Development of fluorinated thienylchalcones as monoamine oxidase-B inhibitors: Design, synthesis, biological evaluation and molecular docking studies

Letters in Organic Chemistry

Volumn 12, Issue 9, 2015, Pages 605-613

  Mathew, Bijo ^a   Uçar, Gülberk ^b   Yabanogclu Çiftçi, Samiye ^b   Baysal, Ipek ^b   Suresh, Jerad ^c   Mathew, Githa Elizabeth ^d   Vilapurathu, Jobin Kunjumon ^d   Nadeena, A M ^a   Nabeela, P ^a   Lakshmi, V ^a   Haridas, Abitha ^a   Fathima, Fajeelath ^a  

^a Department of Pharmaceutical Chemistry Division of Drug Design Grace College of Pharmacy   (India)

^b HACETTEPE UNIVERSITY   (Turkey)

^c MADRAS MEDICAL COLLEGE   (India)

^d Grace College of Pharmacy   (India)

Author keywords

2 Acetyl thiophene; Docking; MAO B; Reversible inhibition; Thienylchalcones

Indexed keywords

EID: 84945542916     PISSN: 15701786     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570178612666150903213416     Document Type: Article

References (38)

1. Hare, M.L.C. Tyramine oxidase: a new enzyme system in liver. Biochem. J. 1928, 22, 968-979.
2. Shih, J.C.; Chen, K.; Ridd, MJ. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 1999, 22, 197-217.
3. Woulters, J. Structural aspects of Monoamine oxidase and its reversible inhibition. Curr. Med. Chem. 1998, 5, 137-162.
4. Yamada, M.; Yasuhara, H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004, 25, 215-221.
5. Binda, C; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A. Structure of human oxidase-B, a drug target for the treatment neurological disorders. Nat. Struct. Biol. 2002, 9, 22-26.
6. Singh, P.; Anand, A.; Kumar, V. Recent developments in biological activities of chalcones: A mini review. Eur. J. Med. Chem. 2014, 85, 758-777.
7. Afzal, O.; Bawa, S.; Kumar, S.; Kumar, R.; Hassan, Md. Q. Design, synthesis and evaluation of novel 2-piperidinyl quinoline chalcones/amines as potential antidepressant agents. Lett. Drug Des. Discov. 2013, 10, 75-85.
8. Tanaka, S.; Kuwai, Y.; Tabata, M. Isolation of Monoamine oxidase from Glycyrrhiza uralensis roots and the structure activity relationship. Planta Med. 1987, 53, 5-8.
9. Hatano, T.; Fukuda, T.; Miyase, T.; Noro, T.; Okuda, T. Phenolic constituents licorice III. Structures of Glicoricone and Licofura-none and inhibitory effects of licorice constituents on monoamine oxidase enzyme. Chem. Pharm. Bull. 1991, 39, 1238-1243.
10. Pan X, Kong LD, Zhang Y, Cheng C.H., Tan RX. In vitro inhibition of rat monoamine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis. Acta Pharmacol. Sinica 2000, 21, 949-953.
11. Haraguchi, H.; Tanaka, Y.; Kabbash, A.; Fujioka, T.; Ishizu, T.; Yagi, A. Monoamine oxidase inhibitors from Gentiana Lutea. Phytochemistry 2004, 65, 2255-2260.
12. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Rossi, F.; Yanez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors. J. Med. Chem. 2009, 52, 2818-2824.
13. Evranos-Aksöz, B.; Yabanoglu-Çiftçi, S.; Uçar, G.; Yelekçi, K.; Ertan, R. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: Monoamine oxidase inhibitory activities and docking studies. Bioorg. Med. Chem. Lett. 2014, 24, 3278-3284.
14. Morales-Camilo, N.; Salas, CO.; Sanhueza, C; Espinosa-Bustos, C; Sepúlveda-Boza, S.; Reyes-Parada, M.; Gonzalez-Nilo, F.; Caroli-Rezende, M.; Fierro, A. Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO-B Inhibitors. Chem. Biol. Drug Des. 2015, 85, 685-695.
15. Mathew, B.; Mathew G.E.; Uçar, G.; Baysal, I.; Suresh, J.; Vilapurathu, J.K.; Prakasan, A.; Suresh, J.K.; Thomas, A. Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies. Bioorg. Chem. 2015, 62, 22-29.
16. Robinson, S.J.; Petzer, J.P.; Petzer, A.; Bergh, J.J.; Lourens, A.C.U. Selected furanochalcones as inhibitors of monoamine oxidase. Bioorg. Med. Chem. Lett. 2013, 23, 4985-4989.
17. Jo. G.; Ahn. S.; Kim, B.G.; Park, H.R.; Kim, Y.H.; Cho, A.H.; Koh, D.; Chong, Y.; Ahn, J.H.; Lim, Y. Chromenyl chalcones with inhibitory effects on monoamine oxidase B. Biorg. Med. Chem. 2013, 21, 7890-7897.
18. Ucar, G.; Gokhan, N.; Yesilada, A.; Bilgin, A.A. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci. Lett. 2005, 382, 327-331.
19. Gokhan, N.; Yesilada, A.; Ucüar, G.; Erol, K.; Bilgin, A.A. 1-Nsubstituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and evaluation as MAO inhibitors. Arch. Pharm. (Weinheim. Ger) 2003, 336, 362-371.
20. Kelekci, N.G.; Koyunoglu, S.; Yabanoglu, S.; Yelekci, K.; Ozgen, O.; Ucar, G.; Erol, K.; Kendi, E.; Yesiladan, A. New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation and structural determinants of MAO-A and MAO-B selectivity. Bioorg. Med. Chem. 2009, 17, 675-689.
21. Mathew, B.; Suresh, J.; Anbazhagan, S. Synthesis, preclinical evaluation and antidepressant activity of 5-substituted phenyl-3-(thiophen-2-yl)-4, 5-dihydro-1h-pyrazole-1-carbothioamide. EXCLI J. 2014, 13, 437-445.
22. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Carradori, S.; Alcaro, S.; Ortuso, F.; Yáñez, M. Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl) hydrazones. J. Med. Chem. 2008, 51, 4874-4880.
23. Anderson, M.C.; Hasan, F.; McCrodden, J.M.; Tipton, K.F. Monoamine oxidase inhibitors and the cheese effect. Neurochem. Res. 1993, 18, 1145-1149.
24. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis-and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun. 2006, 344, 688-695.
25. Turkmenoglu, F.P.; Baysal, I.; Ciftci-Yabanoglu, S.; Yelekci, K.; Temel, H.; Pasa, S.; Ezer, N.; Çalls, I.; Ucar, G. Flavonoids from sideritis species: human monoamine oxidase (hmao) inhibitory activities, molecular docking studies and crystal structure of xanthomicrol. Molecules. 2015; 20, 7454-7473.
26. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
27. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Bizzarri, B.; Chimenti, P.; Granese, A.; Yáñez, M.; Orallo, F. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3, 5-di(hetero)aryl-4, 5-dihydro-(1 H)-pyrazole derivatives. Eur. J. Med. Chem. 2010, 45, 800-804.
28. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Autodock4 and AutoDock-Tools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 16, 2785-2791.
29. De Colibus, L.; Li, M.; Binda, C; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. U. S. A. 2005, 106, 12684-12689.
30. Nayak, B.V.; Ciftci-Yabanoglu, S.; Singh, S.; Jagrat, M.; Sinha, B.N.; Ucar, G.; Jayaprakash, V. Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives. Eur. J. Med. Chem. 2013, 69, 762-767.
31. Mathew, B.; Suresh, J.; Anbazhagan, S. Proposed interaction of some novel antidepressant pyrazolines against monoamine oxidase isoforms. Molecular docking studies and PASS assisted in silico approach. Biomed. Aging Pathol. 2014, 4, 297-301.
32. Knoll, J.; Miklya, I. Multiple, small dose administration of (-) deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch. Int. Pharmacodyn. Ther. 1994, 328, 1-15.
33. Secci, D.; Carradori, S.; Bolascoa, A.; Bizzarria, B.; D'Ascenzioa, M.; Maccioni, E. Discovery and optimization of pyrazoline derivatives as promising Monoamine oxidase inhibitors. Curr. Top. Med. Chem., 2012, 12, 2240-2257.
34. Mathew, B.; Suresh, J.; Anbazhagan, S.; Mathew, G.E. Pyrazoline: A promising scaffold for the inhibition of Monoamine oxidase. Cent. Nerv. Syst. agents Med. Chem. 2013, 13, 195-206.
35. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, D.E.; Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 2009, 9, 22-26.
36. Legoabe, L.; Kruger, J.; Petzer, A.; Bergh, J.J.; Petzer. J.P. Monoamine oxidase inhibition by selected anilide derivatives. Eur. J. Med. Chem. 2011, 46, 5162-5174.
37. Petzer, A.; Grobler, P.; Bergh, J.J.; Petzer, J.P. Inhibition of mono-amine oxidase by selected phenylalkylcaffeine analogues. J. Pharm. Phamacol. 2014; 66, 677-687.
38. Edmondson, D.E.; Mattevi, A.; Binda, C.; Li, M.; Hubalek, F. Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 2004, 11, 1983-1993.